Does Methamphetamine in Ankara Xylazine Cases Prove One Combined Drug Product?
Methamphetamine was co-detected in 28% of Ankara’s xylazine-positive cases, but the finding does not prove the substances came from one product or were used together at one time.
The reported subset
Erol Öztürk and colleagues tested selected biological samples from suspected drug users in Ankara during 2024. They detected xylazine in 28 cases. The 28% methamphetamine figure is within those positives, not among all 9,123 tested samples.
What the samples do not reveal
A biological specimen can reflect exposures over an interval. The authors lacked information on the route and reasons for combined use. They did not pair each person’s result with a verified source product. Co-detection therefore cannot establish product composition, dose timing or the cause of an adverse event.
Individual review
Examine the actual toxicology, timing, product evidence, treatment history and clinical course. State the cohort observation accurately while leaving the source and effect of each substance open unless case-specific evidence resolves them.
Source: Erol Öztürk Y, Yeter O, Aslıyüksek H, Oztuna A, Sezigen S, Demirel G. The first report from Ankara on the presence of xylazine abuse in blood and urine samples using a validated LC-HRMS method. International Journal of Legal Medicine. 2025;139:2695–2705. doi:10.1007/s00414-025-03562-7



